Pharming Group N.V. (PHAR) Stock Analysis

Q: What is the PHAR stock price target?

Take-profit $29.41 (+76.6% upside). Target $29.41 (+76.6%), stop $15.59 (−6.8%), A.R:R 12.1:1.

Range Bound setup

HoldVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $16.65, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak.

$16.65+76.6% A.UpsideScore 6.6/10#7 of 158 Biotechnology

Stop $15.59Target $29.41(analyst − 15%)A.R:R 12.1:1

Analyst target$34.60+107.8%4 analysts

$29.41our TP

$16.65price

$34.60mean

$41

Hold if already holding. Not a fresh buy at $16.65, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: RSI 44 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 6.6/10, moderate confidence.

Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear). Suitability: aggressive.

Thesis

Rewards

Attractive valuation

Strong growth profile

Positive insider activity

Risks

No bear case signals

Key Metrics

P/E (TTM)408.9

P/E (Fwd)44.6

Mkt Cap$1.2B

EV/EBITDA288.1

Profit Mgn0.8%

ROE1.0%

Rev Growth15.0%

Beta0.12

DividendNone

Rating analysts14

Quality Signals

Piotroski F9/9

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.615%1.14

Quality5.415%0.81

Growth8.115%1.21

Momentum4.710%0.47

Sentiment6.610%0.66

Insider Activity7.310%0.73

Peer Rank3.810%0.38

Technical Setup6.05%0.30

Risk Profile8.65%0.43

Catalyst8.35%0.42

Overall (Σ contributions)6.55

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

4.1

Value Rank

4.7

Quality Rank

6.5

GatesMomentum 4.7<5.5 (soft — BUY_NOW allowed but watch)Momentum 4.7>=4.5A.R:R 12.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

44 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $15.74Resistance $18.41

Price Targets

$16

$29

A.Upside+76.6%

A.R:R12.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Analyst Consensus

Analysts14

Consensus4.4/5

Avg Target$35

Earnings

2/4 beats

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PHAR stock a buy right now?

Hold if already holding. Not a fresh buy at $16.65, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: RSI 44 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $29.41 (+76.6%), stop $15.59 (−6.8%), A.R:R 12.1:1. Score 6.6/10, moderate confidence.

What is the PHAR stock price target?

Take-profit target: $29.41 (+76.6% upside). Target $29.41 (+76.6%), stop $15.59 (−6.8%), A.R:R 12.1:1. Stop-loss: $15.59.

Is PHAR overvalued or undervalued?

Pharming Group N.V. trades at a P/E of 408.9 (forward 44.6). TrendMatrix value score: 7.6/10. Verdict: Hold.

What do analysts say about PHAR?

14 analysts cover PHAR with a consensus score of 4.4/5. Average price target: $35.

What does Pharming Group N.V. do?Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and...

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.